AMA Announces New CPT® Category I Codes for Vaccines
Date Posted: Wednesday,
May 14, 2025
The American Medical Association (AMA) has introduced five new Category I CPT® codes and revised one existing code for vaccine reporting. These updates - covering RSV, COVID-19 (SARS-CoV-2), and influenza - were approved by the CPT® Editorial Panel for the 2026 code set and will go into effect July 1, 2025.
What's New
For CPT® purposes, "immunization" encompasses vaccines/toxoids, immune globulins, serum, or recombinant products.
New Codes:
-
90382 – RSV, monoclonal antibody, seasonal dose (0.7 mL), intramuscular
-
91323 – COVID-19 (SARS-CoV-2) vaccine, mRNA-LNP, 10 mcg/0.2 mL, intramuscular
-
90635 – Influenza (H5N1), cell culture-derived, adjuvanted, intramuscular
-
90612 – Trivalent influenza + COVID-19 (SARS-CoV-2) vaccine, mRNA-LNP, 31.7 mcg/0.32 mL, intramuscular
-
90613 – Quadrivalent influenza + COVID-19 (SARS-CoV-2) vaccine, mRNA-LNP, 40 mcg/0.4 mL, intramuscular
Revised Code:
-
90620 – Meningococcal recombinant protein and outer membrane vesicle vaccine, Serogroup B (MenB-4C), 2-dose series, intramuscular
For full descriptions and guidance, refer to the official AMA CPT® immunization code set online.
Source: AMA
